Summary of Study ST001748
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001120. The data can be accessed directly via it's Project DOI: 10.21228/M8XM6R This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST001748 |
Study Title | Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis |
Study Type | Targeted metabolomics |
Study Summary | GUT103 and GUT108, live biotherapeutic products rationally designed to complement missing or underrepresented functions in the dysbiotic microbiome of IBD patients; they address upstream targets, rather than targeting a single cytokine to block downstream inflammation responses. Systematic colonization experiments in colitis mouse models were performed to test their therapeutic effects. Targeted fecal metabolomics data uploaded here of bile acids, short-chain fatty acids, and tryptophan metabolites provides a unique metabolome perspective for evaluation of the therapeutic potential of GUT103 and GUT108. |
Institute | University of North Carolina at Chapel Hill |
Laboratory | Gusto Global LLC. |
Last Name | Lai |
First Name | Yunjia |
Address | 1104 MHRC, 135 Dauer Drive, Chapel Hill, NC 27599, USA |
lai7@live.unc.edu | |
Phone | +1 919-480-5489 |
Submit Date | 2021-04-22 |
Num Groups | 12 |
Publications | Nature Communications |
Raw Data Available | Yes |
Raw Data File Type(s) | mzXML |
Analysis Type Detail | GC-MS/LC-MS |
Release Date | 2021-04-30 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR001838 |
Treatment Summary: | For treatment 200 µl of diluted human donor stool was applied by oral gavage on day 1 to Il10-/- mice. The stool was derived from a single healthy donor, Donor-Y, and was previously found to induce moderate to severe colitis in Il10-/- mice. One gram stool was diluted 100- fold with anaerobic PBS, and vigorously mixed for 5 minutes under anaerobic conditions. For application of GUT-103 and GUT-108, 300µl resuspended strain mixture in anaerobic PBS was applied per mouse by oral gavage. GUT-103 and GUT-108 strains were grown individually, subsequently mixed to equal concentrations (cfu/ml), and provided at a dose of 2.0x10+7 cfu/strain in a total volume of 300 µl. The strain mixture was provided four times via oral gavage on days 15, 17, 22 and 25 (Il10-/- mice) or on days 1, 3, 8 and 11 (Il10+/eGFP mice). |